ABK Biomedical Inc.

ABK Biomedical Inc. is a clinical-stage medical device company founded in 2012 as a spin-off from Dalhousie University in Halifax, Nova Scotia.

The company specializes in researching, developing, and commercializing image-guided embolic therapies for patients with benign and malignant hypervascular tumors. ABK Biomedical focuses on its proprietary platform of inorganic polymer microspheres that are radiopaque, allowing interventional radiologists to monitor embolization materials during oncology procedures. The company develops innovative embolotherapy products, including Eye90 microspheres® for Y90 radioembolization and Easi-VueTM embolic microspheres for treating arteriovenous malformations and hypervascular tumors. ABK Biomedical also utilizes the OccluSystem platform, which provides radiopaque embolic beads visible in X-rays, and is working on drug-eluting beads for targeted chemotherapy delivery. With its own R&D and manufacturing facilities, ABK Biomedical aims to enhance treatment outcomes and personalize therapies for interventional radiologists and oncologists.